<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The neuroprotective effect of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, a peroxisome proliferator-activated receptor γ (PPARγ) <z:chebi fb="4" ids="48705">agonist</z:chebi>, has been investigated using both in vivo and in vitro models of global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in CD1 mice </plain></SENT>
<SENT sid="1" pm="."><plain>Behavioral tests were carried out prior to and at various times (up to 14 days) subsequent to bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by reperfusion </plain></SENT>
<SENT sid="2" pm="."><plain>Mice at each time point were euthanized under anesthesia and the brain was removed, serially sliced and stained with 1% triphenyltetrazolium (TTC) to quantify <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="3" pm="."><plain>Administration of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (5 or 10 mg/kg, i.p.) 10 min prior to occlusion significantly reduced the postsurgical mortality rate (10-11 vs. 36%, P &lt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>The higher dose of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (10 mg/kg) also significantly reduced the mean area of brain <z:mpath ids='MPATH_124'>infarct</z:mpath> at 1, 3, 7 and 14 days post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, reduced post-occlusion deficits in <z:mp ids='MP_0001513'>limb grasping</z:mp> and forelimb placing at various time points, and reduced total <z:chebi fb="95" ids="16301">nitrite</z:chebi> concentration in serum and brain homogenate at day 7 post-occlusion </plain></SENT>
<SENT sid="5" pm="."><plain>To model global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in vitro, coronal brain slices were incubated in oxygenated artificial cerebrospinal fluid (ACSF) in the presence of either <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> (1 mM) or <z:chebi fb="17" ids="16240">hydrogen peroxide</z:chebi> (<z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi>) (5 μM) for 30 min </plain></SENT>
<SENT sid="6" pm="."><plain>Both <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi> and <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> caused significant tissue damage, and co-incubation with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (5 μM) significantly reduced <z:chebi fb="0" ids="16240">H(2)O(2)</z:chebi>-induced damage but did not significantly reduce <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi>-induced brain damage in this model </plain></SENT>
<SENT sid="7" pm="."><plain>Our observations provide further evidence for a neuroprotective effect of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> in <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
</text></document>